| Not Yet Recruiting | Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Non Small Cell Lung Cancer, Respiratory Tract Neoplasm | Phase 2 | 2026-03-15 |
| Recruiting | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung, Respiratory Tract Neoplasms | Phase 2 | 2026-02-28 |
| Recruiting | PALACE: Cemiplimab Trial According to ctDNA Levels Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer | Phase 2 | 2025-07-29 |
| Recruiting | Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Sma Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer | Phase 2 | 2025-07-08 |
| Recruiting | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and P Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma | Phase 3 | 2025-02-04 |
| Recruiting | Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation | — | 2024-10-03 |
| Completed | Characteristics of Sexual Dysfunction in Patients With Lung Cancer Lung Cancer, Sexual Dysfunction | — | 2023-07-13 |
| Recruiting | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors NSCLC, Pancoast Tumor | Phase 2 | 2023-05-12 |
| Recruiting | Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Small Cell Lung Cancer Extensive Stage | Phase 2 | 2022-11-07 |
| Active Not Recruiting | Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment | — | 2022-06-17 |
| Recruiting | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radioth Non-small Cell Lung Cancer Stage III, KRAS P.G12C | Phase 2 | 2022-03-21 |
| Recruiting | Pathological Response After Neoadjuvant Treatment on NSCLC Stage IIIA Non-small Cell Lung Cancer | — | 2021-12-13 |
| Completed | Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment Metastatic Non Small Cell Lung Cancer | — | 2021-12-09 |
| Active Not Recruiting | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer | Phase 2 | 2021-11-18 |
| Completed | Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesot Mesothelioma; Lung | Phase 2 | 2021-09-20 |
| Active Not Recruiting | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer | Phase 2 | 2021-06-16 |
| Completed | Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients Lung Cancer, Covid19 | — | 2021-05-06 |
| Active Not Recruiting | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy Non-Small Cell Lung Cancer, Adjuvant Chemotherapy | Phase 3 | 2021-01-13 |
| Terminated | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients Non Small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | 2020-12-02 |
| Completed | Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. Small Cell Lung Cancer (SCLC) | — | 2020-05-21 |
| Active Not Recruiting | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients Lung Cancer, NSCLC, NSCLC Stage IIIB | Phase 2 | 2020-05-04 |
| Completed | Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection Lung Cancer, COVID, Corona Virus Infection | — | 2020-04-15 |
| Active Not Recruiting | NADIM II: Neo-Adjuvant Immunotherapy Non Small Cell Lung Cancer | Phase 2 | 2019-05-15 |
| Completed | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients Non Small Cell Lung Cancer | Phase 2 | 2019-05-15 |
| Completed | Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Non Small Cell Lung Cancer | — | 2019-02-26 |